A. Koehler

发表

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Kam Y. J. Zhang, K. Flaherty, J. Sosman, 2010, Nature.

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling

Markus Thomas, T. Nayak, S. Robinson, 2016, British Journal of Cancer.

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

A. Hauschild, D. Schadendorf, K. Flaherty, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.

J. Baselga, W. Eiermann, A. Lluch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

James X. Song, A. Tolcher, G. Shapiro, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

L. Pusztai, J. Baselga, W. Eiermann, 2008 .

Predictive Biomarkers and Personalized Medicine Research-Based PAM 50 Subtype Predictor Identi fi es Higher Responses and Improved Survival Outcomes in HER 2-Positive Breast Cancer in the NOAH Study

M. Cheang, W. Eiermann, A. Prat, 2014 .

Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).

K. Flaherty, J. Sosman, A. Ribas, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab.

K. Stubenrauch, Uwe Wessels, A. Koehler, 2015, Journal of pharmaceutical and biomedical analysis.

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

M. Hidalgo, T. Nayak, J. Albanell, 2014 .

Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma.

K. Flaherty, J. Sosman, A. Ribas, 2012 .